![David Planchard: New option in the 1st line strategy for NSCLC EGFRmut patients](https://oncodaily.com/pub/uploads/2024/07/planchard-e1720714906810.png)
Photo of David Planchard from Oncostream.com
Jul 13, 2024, 11:17
David Planchard: New option in the 1st line strategy for NSCLC EGFRmut patients
David Planchard, Thoracic Oncologist at Gustave Roussy, shared on LinkedIn:
“Great news, a new option in our 1st line strategy for NSCLC EGFRmut patients! To be discussed especially in our patients with brain metastases, ctDNA+ or high tumor load.”
Source: David Planchard/LinkedIn
Aug 26, 2024, 06:10